Patricia Jimenez Guzman, MD
Sleep Medicine · Leesburg, VANPI 1396242707
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 27.0% of the total. Reporting peaked in 2023 at $769 and has fallen 61.4% since, to $297 in 2025.
Across 59 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$490
- Inspire Medical Systems, Inc.$459
- Harmony Biosciences LLC$363
- Avadel CNS Pharmaceuticals, LLC$274
- Jazz Pharmaceuticals Inc.$155
- Idorsia Pharmaceuticals US Inc$41
- plus $36 from 1 others
What the payments were for
- Food & beverage$1,70694%
- Education$1126%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 21 | $490 |
| Inspire Medical Systems, Inc. | 3 | $459 |
| Harmony Biosciences LLC | 15 | $363 |
| Avadel CNS Pharmaceuticals, LLC | 9 | $274 |
| Jazz Pharmaceuticals Inc. | 6 | $155 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| ZOLL Respicardia, Inc. | 2 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,818 in reported general payments places this provider in the 60th percentile of 74 sleep medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxepin Hcl | 30 | $550 |
| Zolpidem Tartrate ErZolpidem Tartrate | 15 | $429 |
| Eszopiclone | 19 | $253 |
| Zolpidem Tartrate | 19 | $193 |
| Gabapentin | 11 | $109 |
| Trazodone Hcl | 20 | $86 |
| Zaleplon | 17 | $78 |
| Montelukast Sodium | 13 | $47 |
| Amitriptyline Hcl | 12 | $32 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in Leesburg
- Marc RaphaelsonLeesburg$47K
- Shahriar ShahzeidiLeesburg$27K
- Swathi CharyaLeesburg$3K
- Sean RotoloLeesburg$3K
- Jessica RiggsLeesburg$3K
- Charu SabharwalLeesburg$2K
- James TomkinsonLeesburg$2K
- Hwan KimLeesburg$2K
- Keisha SullivanLeesburg$2K
- Pushkar DeshpandeLeesburg$913
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.